Your shopping cart is empty

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Generic Line > Hospira: More Troubles, Some Progress in Manufacturing Remediation

Generic Line

Aug. 15, 2012 | Vol. 29 No. 16

Hospira: More Troubles, Some Progress in Manufacturing Remediation

Amid lingering quality issues at a number of its manufacturing plants, Hospira reported some success in its discussions with the FDA but notes there are more trouble spots than the company previously thought.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Teva Ponies Up $2 Billion to Settle Protonix Patent Flap Teva Ponies Up $2 Billion to Settle Protonix Patent Flap Drugmaker: REMS Requirement Puts Innovators in Anti-Trust Crosshairs Texas Dismisses Biotech-Backed Biosimilar Substitution Bill

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.